dcb

DCB (3,3'-dichlorobenzaldazine) 是 mGluR5 的变构配体，显示出 3,3'-二甲氧基苯扎嗪 (DMeOB) 的负调节作用。 DCB 在 3,3'-二氟苯扎嗪 (DFB) 的帮助下阻断 mGluR 的正变构调节。

Z-Asp-CH2-DCB 是广谱半胱天冬酶的不可逆抑制剂。

Tylophorine analog DCB-3503 is a potential anticancer and immunosuppressive agent. DCB-3503 suppresses the translation of cellular regulatory proteins, including cyclin D1, at the elongation step. DCB-3503 allosterically regulates the ATPase and chaperone activities of HSC70 by promoting ATP hydrolysis in the presence of specific RNA binding motifs (AUUUA) of cyclin D1 mRNA.

L594881, also known as 3',4'-Dichlorobenzamil or DCB, is an inhibitor of Na+ Ca2+ exchanger, Na+ transport and sarcoplasmic reticulum Ca2+ release channels. L594881 can inhibit Na+ Ca2+ exchanger, Na+ transport and sarcoplasmic reticulum Ca2+ release channels.

Tylophorine, (-)- is a biomedical.

dCBP-1 是基于Cereblon 配体的p300 CBP 的选择性双功能降解剂。dCBP-1可以有效的杀死多发性骨髓瘤细胞，并降低驱动 MYC 表达的致癌增强子活性。

DCBA 是驱虫剂 N-N-diethyl-meta-toluamide (DEET) 的代谢物。尿液中 DCBA 的浓度是评估 DEET 暴露程度的指标。

DCBCI0901 is an inhibitor of phosphatidylinositide 3-kinase (PI3K), raptor-mTOR (mTOR complex 1 or mTORC1) and rictor-mTOR (mTOR complex 2 or mTORC2) with potential antineoplastic activity.

m-Chloro-DCBA is a bioactive chemical.

m-Fluoro-DCBA is a bioactive chemical

DC-BPi-11为溴域PHD转录因子(BPTF)抑制剂，其IC50值为698 nM，对白血病细胞增殖展现出显著的抑制效果。

DC-BPi-03 是一种新型 BPTF-BRD 抑制剂（IC50 为 698.3 nM），具有潜在的抗癌户型，可用于研究白血病。

5’-O-DMTr-2’,2’-difluoro-dC(Bz)-methyl phosphonamidite 是一种广泛具有抗肿瘤活性的嘌呤核苷类似物，主要用于靶向惰性淋巴系统恶性肿瘤。其抗癌机制主要通过抑制 DNA 合成和诱导细胞凋亡 (apoptosis) 来实现。

Rev dC(Bz)-5'-amidite 是一种具有广泛抗肿瘤活性的嘌呤核苷类似物，主要针对惰性淋巴系统恶性肿瘤。其抗癌机制包括抑制 DNA 合成和诱导细胞凋亡(apoptosis)等作用。

DMT-5Me-dC(Bz)-CE Phosphoramidite 用于生产锁定核酸（LNAs），旨在优化荧光寡核苷酸探针的设计，从而提升其光谱性质和对目标的结合能力。

DC-BPi-11 hydrochloride是一种作用于溴域PHD转录因子(BPTF)的抑制剂，具有698 nM的IC50值。它对白血病细胞的增殖表现出显著的抑制效果。

Nucleoside Derivatives - Fluoro-modified nucleosides; 2'-Modified nucleosides; Nucleoside Phosphoramidites

3'-dC(Bz)-2'-phosphoramidite is a Nucleoside Phosphoramidite.

Nucleoside phosphonamidite;Fluoro-modified nucleosides;2'-Modified nucleosides

OPC-167832 is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis[1]. OPC-167832 exhibits very low MICs against laboratory strains of M. tuberculosis H37Rv (MIC: 0.0005 μg ml) and Kurono (MIC: 0.0005 μg ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria[1].The IC90 values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027 μg ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004 μg ml or higher[1]. OPC-167832 (oral administration; 0.625-10 mg kg) exhibits a good pharmacokinetic characteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1 2) of 1.3 h to 2.1 h OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the Cmax and AUCt of OPC-167832 in plasma and the lungs shows dose dependency[1].OPC-167832 (oral administration; 0.625-10 mg kg; 4 weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625 mg kg to 2.5 mg kg. In a M. tuberculosis Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone[1].[1].OPC-167832 (oral gavage; 2.5 mg kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate[1]. [1]. Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.